PortalPublikationenTherapie bei MDR-, prä-XDR-, XDR-Tuberkulose und Rifampicin-...

Therapie bei MDR-, prä-XDR-, XDR-Tuberkulose und Rifampicin-Resistenz oder bei Medikamentenunverträglichkeit gegenüber mindestens Rifampicin

Standard

Therapie bei MDR-, prä-XDR-, XDR-Tuberkulose und Rifampicin-Resistenz oder bei Medikamentenunverträglichkeit gegenüber mindestens Rifampicin. / Otto-Knapp, Ralf; Bauer, Torsten; Brinkmann, Folke; Feiterna-Sperling, Cornelia; Friesen, Inna; Geerdes-Fenge, Hilte; Hartmann, Pia; Häcker, Brit; Hauer, Barbara; Haas, Walter; Heyckendorf, Jan; Kuhns, Martin; Lange, Christoph; Maurer, Florian P; Nienhaus, Albert; Priwitzer, Martin; Richter, Elvira; Salzer, Helmut J F; Schoch, Otto; Schönfeld, Nicolas; Schaberg, Tom.

in: PNEUMOLOGIE, Jahrgang 78, Nr. 1, 01.2024, S. 35-46.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Otto-Knapp, R, Bauer, T, Brinkmann, F, Feiterna-Sperling, C, Friesen, I, Geerdes-Fenge, H, Hartmann, P, Häcker, B, Hauer, B, Haas, W, Heyckendorf, J, Kuhns, M, Lange, C, Maurer, FP, Nienhaus, A, Priwitzer, M, Richter, E, Salzer, HJF, Schoch, O, Schönfeld, N & Schaberg, T 2024, 'Therapie bei MDR-, prä-XDR-, XDR-Tuberkulose und Rifampicin-Resistenz oder bei Medikamentenunverträglichkeit gegenüber mindestens Rifampicin', PNEUMOLOGIE, Jg. 78, Nr. 1, S. 35-46. https://doi.org/10.1055/a-2182-1609

APA

Otto-Knapp, R., Bauer, T., Brinkmann, F., Feiterna-Sperling, C., Friesen, I., Geerdes-Fenge, H., Hartmann, P., Häcker, B., Hauer, B., Haas, W., Heyckendorf, J., Kuhns, M., Lange, C., Maurer, F. P., Nienhaus, A., Priwitzer, M., Richter, E., Salzer, H. J. F., Schoch, O., ... Schaberg, T. (2024). Therapie bei MDR-, prä-XDR-, XDR-Tuberkulose und Rifampicin-Resistenz oder bei Medikamentenunverträglichkeit gegenüber mindestens Rifampicin. PNEUMOLOGIE, 78(1), 35-46. https://doi.org/10.1055/a-2182-1609

Vancouver

Otto-Knapp R, Bauer T, Brinkmann F, Feiterna-Sperling C, Friesen I, Geerdes-Fenge H et al. Therapie bei MDR-, prä-XDR-, XDR-Tuberkulose und Rifampicin-Resistenz oder bei Medikamentenunverträglichkeit gegenüber mindestens Rifampicin. PNEUMOLOGIE. 2024 Jan;78(1):35-46. https://doi.org/10.1055/a-2182-1609

Bibtex

@article{784e995c4682464c8fd342f6eaa074c3,
title = "Therapie bei MDR-, pr{\"a}-XDR-, XDR-Tuberkulose und Rifampicin-Resistenz oder bei Medikamentenunvertr{\"a}glichkeit gegen{\"u}ber mindestens Rifampicin",
abstract = "In December 2022, based on the assessment of new evidence, the World Health Organization (WHO) updated its guidelines for the treatment of drug-resistant tuberculosis (TB). The evaluation of both, these recommendations, and the latest study data, makes it necessary to update the existing guidelines on the treatment of at least rifampicin-resistant tuberculosis for the German-speaking region, hereby replacing the respective chapters. A shortened MDR-TB treatment of at least 6 month using the fixed and non-modifiable drug combination of bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaLM) is now also recommended for Germany, Austria, and Switzerland under certain conditions. This recommendation applies to TB cases with proven rifampicin resistance, including rifampicin monoresistance. For treatment of pre-extensively drug resistant TB (pre-XDR-TB), an individualized treatment for 18 months adjusted to resistance data continues to be the primary recommendation. The non-modifiable drug combination of bedaquiline, pretomanid, and linezolid (BPaL) may be used alternatively in pre-XDR TB if all prerequisites are met. The necessary prerequisites for the use of BPaLM and BPaL are presented in this amendment to the S2k guideline for 'Tuberculosis in adulthood'.",
author = "Ralf Otto-Knapp and Torsten Bauer and Folke Brinkmann and Cornelia Feiterna-Sperling and Inna Friesen and Hilte Geerdes-Fenge and Pia Hartmann and Brit H{\"a}cker and Barbara Hauer and Walter Haas and Jan Heyckendorf and Martin Kuhns and Christoph Lange and Maurer, {Florian P} and Albert Nienhaus and Martin Priwitzer and Elvira Richter and Salzer, {Helmut J F} and Otto Schoch and Nicolas Sch{\"o}nfeld and Tom Schaberg",
note = "Thieme. All rights reserved.",
year = "2024",
month = jan,
doi = "10.1055/a-2182-1609",
language = "Deutsch",
volume = "78",
pages = "35--46",
journal = "PNEUMOLOGIE",
issn = "0934-8387",
publisher = "Georg Thieme Verlag KG",
number = "1",

}

RIS

TY - JOUR

T1 - Therapie bei MDR-, prä-XDR-, XDR-Tuberkulose und Rifampicin-Resistenz oder bei Medikamentenunverträglichkeit gegenüber mindestens Rifampicin

AU - Otto-Knapp, Ralf

AU - Bauer, Torsten

AU - Brinkmann, Folke

AU - Feiterna-Sperling, Cornelia

AU - Friesen, Inna

AU - Geerdes-Fenge, Hilte

AU - Hartmann, Pia

AU - Häcker, Brit

AU - Hauer, Barbara

AU - Haas, Walter

AU - Heyckendorf, Jan

AU - Kuhns, Martin

AU - Lange, Christoph

AU - Maurer, Florian P

AU - Nienhaus, Albert

AU - Priwitzer, Martin

AU - Richter, Elvira

AU - Salzer, Helmut J F

AU - Schoch, Otto

AU - Schönfeld, Nicolas

AU - Schaberg, Tom

N1 - Thieme. All rights reserved.

PY - 2024/1

Y1 - 2024/1

N2 - In December 2022, based on the assessment of new evidence, the World Health Organization (WHO) updated its guidelines for the treatment of drug-resistant tuberculosis (TB). The evaluation of both, these recommendations, and the latest study data, makes it necessary to update the existing guidelines on the treatment of at least rifampicin-resistant tuberculosis for the German-speaking region, hereby replacing the respective chapters. A shortened MDR-TB treatment of at least 6 month using the fixed and non-modifiable drug combination of bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaLM) is now also recommended for Germany, Austria, and Switzerland under certain conditions. This recommendation applies to TB cases with proven rifampicin resistance, including rifampicin monoresistance. For treatment of pre-extensively drug resistant TB (pre-XDR-TB), an individualized treatment for 18 months adjusted to resistance data continues to be the primary recommendation. The non-modifiable drug combination of bedaquiline, pretomanid, and linezolid (BPaL) may be used alternatively in pre-XDR TB if all prerequisites are met. The necessary prerequisites for the use of BPaLM and BPaL are presented in this amendment to the S2k guideline for 'Tuberculosis in adulthood'.

AB - In December 2022, based on the assessment of new evidence, the World Health Organization (WHO) updated its guidelines for the treatment of drug-resistant tuberculosis (TB). The evaluation of both, these recommendations, and the latest study data, makes it necessary to update the existing guidelines on the treatment of at least rifampicin-resistant tuberculosis for the German-speaking region, hereby replacing the respective chapters. A shortened MDR-TB treatment of at least 6 month using the fixed and non-modifiable drug combination of bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaLM) is now also recommended for Germany, Austria, and Switzerland under certain conditions. This recommendation applies to TB cases with proven rifampicin resistance, including rifampicin monoresistance. For treatment of pre-extensively drug resistant TB (pre-XDR-TB), an individualized treatment for 18 months adjusted to resistance data continues to be the primary recommendation. The non-modifiable drug combination of bedaquiline, pretomanid, and linezolid (BPaL) may be used alternatively in pre-XDR TB if all prerequisites are met. The necessary prerequisites for the use of BPaLM and BPaL are presented in this amendment to the S2k guideline for 'Tuberculosis in adulthood'.

U2 - 10.1055/a-2182-1609

DO - 10.1055/a-2182-1609

M3 - SCORING: Zeitschriftenaufsatz

C2 - 37931778

VL - 78

SP - 35

EP - 46

JO - PNEUMOLOGIE

JF - PNEUMOLOGIE

SN - 0934-8387

IS - 1

ER -